Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON 2 10 versus LYPQOZET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON 2 10 versus LYPQOZET.
ETRAFON 2-10 vs LYPQOZET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETRAFON 2-10 is a combination of the phenothiazine antipsychotic perphenazine and the tricyclic antidepressant amitriptyline. Perphenazine blocks dopamine D2 receptors, reducing dopaminergic neurotransmission in the mesolimbic pathway, while amitriptyline inhibits serotonin and norepinephrine reuptake, enhancing monoaminergic signaling.
LYPQOZET is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic serotonin transporter, leading to increased synaptic levels of serotonin.
1-2 tablets (perphenazine 2 mg / amitriptyline 10 mg) orally 3-4 times daily; max 8 tablets/day.
Oral, 75 mg once daily.
None Documented
None Documented
The terminal elimination half-life is approximately 9-10 hours for perphenazine and 18-24 hours for amitriptyline; amitriptyline's active metabolite nortriptyline has a half-life of 18-44 hours, necessitating once-daily dosing for maintenance.
Terminal elimination half-life is 22-28 hours in adults, allowing once-daily dosing. Extended half-life supports sustained therapeutic levels.
Elimination is primarily renal (50-70% as metabolites, <5% unchanged) and biliary/fecal (30-50% as metabolites).
Primarily renal (75% unchanged) and fecal/biliary (20% as metabolites); <5% unchanged in feces.
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic